1
|
Roy AS, Banerjee K, Roy P, Shil R, Ravishankar R, Datta R, Sen A, Manna S, Ghosh TK, Mukherjee G, Rana TK, Kundu S, Nayak SS, Pandey R, Paul D, Atreya K, Basu S, Mukhopadhyay S, Pandit D, Kulkarni MS, Bhattacharya C. Measurement of energy and directional distribution of neutron ambient dose equivalent for the 7Li(p,n) 7Be reaction. Appl Radiat Isot 2024; 204:111140. [PMID: 38070360 DOI: 10.1016/j.apradiso.2023.111140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 11/13/2023] [Accepted: 12/02/2023] [Indexed: 12/31/2023]
Abstract
Double differential neutron fluence distributions were measured in the 7Li(p,n)7Be reaction for proton beam energies 7, 9 and 12 MeV. Seven liquid scintillator based detectors were employed to measure neutron fluence distributions using the Time of Flight technique. Neutron ambient dose equivalents were determined from the measured fluence distribution using ICRP (International Commission on Radiological Protection) recommended fluence to dose equivalent conversion coefficients. Neutron dose equivalents were also measured using a conventional BF3 detector based REM counter. Ambient dose equivalent measured by the REM counter is found to be in agreement with that determined from the neutron fluence spectra within their uncertainties. Angular distributions of the ambient dose equivalents were also determined from the measured fluence distributions at different angles.
Collapse
Affiliation(s)
- A S Roy
- Health Physics Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India
| | - K Banerjee
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India.
| | - Pratap Roy
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - R Shil
- Visva Bharati University, Santiniketan, Bolpur, West Bengal 731235, India
| | - R Ravishankar
- Health Physics Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - R Datta
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; RP&AD, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - A Sen
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - S Manna
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - T K Ghosh
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - G Mukherjee
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - T K Rana
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - S Kundu
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - S S Nayak
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - R Pandey
- Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - D Paul
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - K Atreya
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - S Basu
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - S Mukhopadhyay
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - Deepak Pandit
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| | - M S Kulkarni
- Health Physics Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India
| | - C Bhattacharya
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India; Variable Energy Cyclotron Centre, 1/AF, Bidhannagar, Kolkata 700064, India
| |
Collapse
|
2
|
Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, Kumar SN, Mukherjee S, Gore ST, Krishnamurthy NR, Marappan S, Nayak SS, Nellore K, Balasubramanian WR, Bhumireddy A, Giri S, Gopinath S, Samiulla DS, Daginakatte G, Basavaraju A, Chelur S, Eswarappa R, Belliappa C, Subramanya HS, Booher RN, Ramachandra M, Samajdar S. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med Chem Lett 2020. [PMID: 33335659 DOI: 10.1021/acsmedchemlett.0c0025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2023] Open
Abstract
Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene's compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines. Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure. The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia.
Collapse
Affiliation(s)
- Venkateshwar Rao Gummadi
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Anima Boruah
- Aurigene Discovery Technologies Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Bharathi Raja Ainan
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Brahma Reddy Vare
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Srinivas Manda
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Hari Prakash Gondle
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shiva Nagendra Kumar
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Subhendu Mukherjee
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Suraj T Gore
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Narasimha Rao Krishnamurthy
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sivapriya Marappan
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shilpa S Nayak
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Kavitha Nellore
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Wesley Roy Balasubramanian
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Archana Bhumireddy
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sreevalsam Gopinath
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Dodheri S Samiulla
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Girish Daginakatte
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Aravind Basavaraju
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Rajesh Eswarappa
- Aurigene Discovery Technologies Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Charamanna Belliappa
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Hosahalli S Subramanya
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Robert N Booher
- Curis Inc., 4 Maguire Road, Lexington, Massachusetts 02421, United States
| | - Murali Ramachandra
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Susanta Samajdar
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| |
Collapse
|
3
|
Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, Kumar SN, Mukherjee S, Gore ST, Krishnamurthy NR, Marappan S, Nayak SS, Nellore K, Balasubramanian WR, Bhumireddy A, Giri S, Gopinath S, Samiulla DS, Daginakatte G, Basavaraju A, Chelur S, Eswarappa R, Belliappa C, Subramanya HS, Booher RN, Ramachandra M, Samajdar S. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med Chem Lett 2020; 11:2374-2381. [PMID: 33335659 DOI: 10.1021/acsmedchemlett.0c00255] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 10/06/2020] [Indexed: 02/08/2023] Open
Abstract
Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene's compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines. Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure. The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia.
Collapse
Affiliation(s)
- Venkateshwar Rao Gummadi
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Anima Boruah
- Aurigene Discovery Technologies Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Bharathi Raja Ainan
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Brahma Reddy Vare
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Srinivas Manda
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Hari Prakash Gondle
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shiva Nagendra Kumar
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Subhendu Mukherjee
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Suraj T. Gore
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Narasimha Rao Krishnamurthy
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sivapriya Marappan
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shilpa S. Nayak
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Kavitha Nellore
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Wesley Roy Balasubramanian
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Archana Bhumireddy
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Sreevalsam Gopinath
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Dodheri S. Samiulla
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Girish Daginakatte
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Aravind Basavaraju
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Rajesh Eswarappa
- Aurigene Discovery Technologies Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Charamanna Belliappa
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Hosahalli S. Subramanya
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Robert N. Booher
- Curis Inc., 4 Maguire Road, Lexington, Massachusetts 02421, United States
| | - Murali Ramachandra
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| | - Susanta Samajdar
- Aurigene Discovery Technologies Ltd., 39-40 KIADB Industrial Area, Electronic City Phase II, Bangalore 560 100, India
| |
Collapse
|
4
|
Poddutoori R, Rajagopalan S, Mukherjee S, Marappan S, D. S. S, Sivakumar S, Nayak SS, M V R, TS D, Kondela S, Tgore S, Dhudashiya AA, K. B C, A B A, A A, S P, Pathange HS, Antony T, Jaleel M, Giri S, Daginakatte G, Nellore K, Chelur S, Ramachandra M, Samajdar S. Abstract 4418: Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cyclin-dependent kinase 12 (CDK12) is a transcription-associated protein that plays a critical role in DNA damage response, splicing, pre-mRNA processing and is crucial for maintaining genomic stability. CDK12 associated with Cyclin K (CycK) regulates transcription elongation by phosphorylating RNA polymerase II (RNAP II) at Serine 2 (pS2) in the C-terminal domain (CTD). Overexpression of CDK12 in various tumor types suggests the possibility that CDK12 has oncogenic properties, similarly to other transcription-associated kinases. Considering its critical role in transcription and RNA processing, CDK12 is emerging as a potential therapeutic target for cancer. Multiple series of potent and selective CDK12 covalent inhibitors were identified by structure-guided and iterative medicinal chemistry approaches. Early lead compounds were optimized towards achieving high on target potency with good selectivity and desirable drug like properties including pharmacokinetic profile to achieve anti-tumour activity. Optimization of early lead compounds from two distinct chemical series resulted in very potent and highly selective CDK12 covalent inhibitors with desirable oral bioavailability. The covalent mode of action for these biochemically potent compounds has been confirmed by CDK12 target engagement assay in the cellular context. These selective inhibitors showed significant anti-proliferative activity in TNBC and other cancer cell lines including those harbouring ETS fusion. Importantly, cell killing is observed in cancer cells but not in normal cells (RWPE1) with short time (2h) and long-time (72h) exposure of these compounds. Anti-proliferative activity is well correlated with the inhibition of pS2 and down-regulation of a number of DNA damage response genes including BRCA1, RAD51, ATM and FANCI. Consistent with the inhibition of genes involved in DNA damage repair, a highly synergistic anti-proliferative activity was observed when treated in combination with cisplatin and PARP inhibitors. Based on the robust efficacy as a single agent in a TNBC mouse xenograft model with one of the optimized leads, the preclinical candidate exhibiting a greater degree of selectivity is being evaluated for efficacy and tolerability in relevant preclinical models.
Citation Format: Ramulu Poddutoori, Sujatha Rajagopalan, Subhendu Mukherjee, Sivapriya Marappan, Samiulla D. S., Sasirekha Sivakumar, Shilpa S Nayak, Ravindra M V, Devaraja TS, Srinivas Kondela, Suraj Tgore, Amit A Dhudashiya, Charamanna K. B, Aravind A B, Amith A, Pavithra S, Hema Sankar Pathange, Thomas Antony, Mahaboobi Jaleel, Sanjeev Giri, Girish Daginakatte, Kavitha Nellore, Shekar Chelur, Murali Ramachandra, Susanta Samajdar. Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4418.
Collapse
Affiliation(s)
| | | | | | | | - Samiulla D. S.
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | | | - Shilpa S Nayak
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Ravindra M V
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Devaraja TS
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Srinivas Kondela
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Suraj Tgore
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | | | - Charamanna K. B
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Aravind A B
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Amith A
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Pavithra S
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | | | - Thomas Antony
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Mahaboobi Jaleel
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | | | - Kavitha Nellore
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| | | | - Susanta Samajdar
- Aurigene Discovery Technologies Ltd, Housr Road, Bangalore, India
| |
Collapse
|
5
|
Poddutoori R, Rajagopalan S, Mukherjee S, Marappan S, S SD, Sivakumar S, Nayak SS, V RM, Murtuza H, S DT, Kondela S, Tgore S, Dhudashiya AA, B CK, Antony T, Daginakatte G, Giri S, Chelur S, Ramachandra M, Pandit C, Samajdar S. Abstract 2384: Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase that participates in various cellular processes such as DNA damage response, splicing and pre-mRNA processing. In association with Cyclin K (CycK), CDK12 regulates transcription elongation by phosphorylating RNA polymerase II (RNAP II) at Serine 2 in the C-terminal domain (CTD). Overexpression of CDK12 in various tumor types suggests the possibility that CDK12 has oncogenic properties, similarly to other transcription-associated kinases. Considering its critical role in transcription and RNA processing CDK12 is emerging as a potential therapeutic target for cancer. Multiple series of potent and selective CDK12 covalent inhibitors were identified by iterative medicinal chemistry efforts and SAR-based approaches. Early compounds were optimized towards attaining good physicochemical properties, high potency, good selectivity and desirable pharmacokinetic profile to achieve anti-tumour activity. Very potent and highly selective CDK12 inhibitors have been identified from two distinct chemical series. The covalent mode of action for these biochemically potent compounds has been confirmed by CDK12 target engagement assay in the cellular context. These selective inhibitors showed significant anti-proliferative activity in TNBC and other cancer cell lines, which correlated with inhibition of pS2 (RNAP II), a bonafide CDK12 substrate and target engagement. In vivo target engagement, PD and efficacy data for optimized compounds with good oral bioavailability in a TNBC (HCC-70) xenograft model along with will be presented.
Citation Format: Ramulu Poddutoori, Sujatha Rajagopalan, Subhendu Mukherjee, Sivapriya Marappan, Samiulla D S, Sasirekha Sivakumar, Shilpa S. Nayak, Ravindra M. V, Hadianawala Murtuza, Devaraja T. S, Srinivas Kondela, Suraj Tgore, Amit A. Dhudashiya, Charamanna K. B, Thomas Antony, Girish Daginakatte, Sanjeev Giri, Shekar Chelur, Murali Ramachandra, Chetan Pandit, Susanta Samajdar. Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2384.
Collapse
Affiliation(s)
| | | | | | | | - Samiulla D S
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | - Ravindra M. V
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Devaraja T. S
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Suraj Tgore
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | | | - Thomas Antony
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Sanjeev Giri
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | | - Chetan Pandit
- Aurigene Discovery Technologies Ltd., Bangalore, India
| | | |
Collapse
|
6
|
Vaideeswar P, Nayak SS, Verma A, Goel NA. Pulmonary miliary papillary/micropapillary adenocarcinoma manifesting as carcinomatous encephalitis. J Postgrad Med 2017; 63:191-193. [PMID: 28272062 PMCID: PMC5525484 DOI: 10.4103/0022-3859.201410] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The histological pattern and the associated molecular aberrations have an important bearing in the prognosis of pulmonary adenocarcinomas. Papillary and micropapillary growth patterns with mutations in epidermal growth factor receptor and anaplastic large-cell lymphoma kinase rearrangements have an aggressive clinical course. We report one such cancer in a 49-year-old woman, where it assumed a miliary pattern in the lungs, and the patient presented with neurological symptoms related to carcinomatous encephalitis, an infrequent metastatic manifestation.
Collapse
Affiliation(s)
- P Vaideeswar
- Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
| | - S S Nayak
- Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
| | - A Verma
- Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
| | - N A Goel
- Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
| |
Collapse
|
7
|
Girisha KM, Nayak SS, Shukla A, Bhat SK. ALOBAR HOLOPROSENCEPHALY, CLEFT LIP/PALATE, URORECTAL SEPTUM MALFORMATION SEQUENCE AND CONGENITAL PERINEAL HERNIA IN A FETUS. Genet Couns 2015; 26:321-325. [PMID: 26625663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We report on a fetus with alobar holoprosencephaly, complete cleft lip and palate, urorectal septum malformation sequence and perineal hernia. To our knowledge this appears to be a novel fetal malformation syndrome.
Collapse
|
8
|
Nayak SS, Ankola AV, Metgud SC, Bolmal U. Effectiveness of mouthrinse formulated from ethanol extract of Terminalia chebula fruit on salivary Streptococcus mutans among 12 to 15 year old school children of Belgaum city: a randomized field trial. J Indian Soc Pedod Prev Dent 2012; 30:231-6. [PMID: 23263427 DOI: 10.4103/0970-4388.105016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES Dental caries is the most prevalent oral disease. Streptococcus mutans plays a major role in the occurrence of dental caries. Many antibacterial agents have been developed against dental caries. However, they lack the qualities of an ideal agent. Thus presently, antibacterial activity of herbal agents is being extensively studied. MATERIALS AND METHODS In the present study, ethanol extract of Terminalia chebula was prepared and mouthrinse was formulated. A total of 60 children meeting the inclusion criteria were randomly divided into study and control group and respective mouthrinses were administered. Salivary Streptococcus mutans count was assessed at 5 and 60 minutes after rinsing and compared with baseline values. Substantivity of the rinse was assessed among 10 children. Mouthrinse was given to the children and salivary Streptococcus mutans counts were assessed at baseline, 6 and 12 hours postrinsing. Mann-Whitney U test was used to assess the variance of factors like Decayed Missed Filled Teeth, plaque scores, and gingival scores. ANCOVA (Analysis of covariance) was used to determine the change in salivary Streptococcus mutans colony forming units taking baseline values as covariates. RESULTS It was observed that there was 44.42% reduction in salivary Streptococcus mutans colony forming units 5 minutes after rinsing as compared with baseline values and 64.14% reduction in Streptococcus mutans colony forming units at 60 minutes after rinsing as compared with baseline values. There was a reduction of 35.48% in salivary Streptococcus mutans colony forming units at 60 minutes after rinsing as compared with 5 minutes sample. CONCLUSION Streptococcus mutans counts were low up to 6 hours postrinsing among 80% of the children.
Collapse
Affiliation(s)
- S S Nayak
- Department of Public Health Dentistry, KLE VK Institute of Dental Sciences, KLE University, Belgaum, Karnataka, India.
| | | | | | | |
Collapse
|
9
|
Nayak SS, Adiga PK, Rai L, Girisha KM. Severe rhizomelic chondrodysplasia punctata in a fetus due to maternal mixed connective tissue disorder. Genet Couns 2012; 23:487-491. [PMID: 23431749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Maternal systemic lupus erythematosus and autoimmune diseases have been extremely rarely reported to cause rhizomelic chondrodysplasia punctata. We report on a fetus aborted spontaneously at 21 weeks of gestation due to complications of maternal mixed connective tissue disorder. The fetus had micrognathia, a depressed nasal bridge, flat nose, long philtrum, short columella and rhizomelia. Radiographic study showed stippling of carpal and tarsal bones, short humeri and coronal clefts in the vertebrae. Ossification centers were present at the lower end of the femora and upper end of the tibiae.
Collapse
Affiliation(s)
- S S Nayak
- Division of Medical Genetics, Department of Pediatrics, Kasturba Medical College, Manipal University, Manipal, India
| | | | | | | |
Collapse
|
10
|
Das S, Sharma S, Sahu SK, Nayak SS, Kar S. New microbial spectrum of epidemic keratoconjunctivitis: clinical and laboratory aspects of an outbreak. Br J Ophthalmol 2008; 92:861-862. [PMID: 18523092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
11
|
Dash DK, Yeligar VC, Nayak SS, Ghosh T, Rajalingam R, Sengupta P, Maiti BC, Maity TK. Evaluation of hepatoprotective and antioxidant activity of Ichnocarpus frutescens (Linn.) R.Br. on paracetamol-induced hepatotoxicity in rats. TROP J PHARM RES 2007. [DOI: 10.4314/tjpr.v6i3.14656] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
12
|
Nayak SS, Ghosh AK, Srikanth K, Debnath B, Jha T. Antitussive activity of Abies webbiana Lindl. leaf extract against sulphur dioxide-induced cough reflex in mice. Phytother Res 2003; 17:930-2. [PMID: 13680827 DOI: 10.1002/ptr.1263] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The methanol extract of A. webbiana Lindl was evaluated for its effect on a cough model induced by sulphur dioxide gas in mice. When administered orally it exhibited significant antitussive activity compared with the control in a dose dependent manner. The antitussive activity of the extract was compared with that of codeine phosphate, a prototype antitussive agent. The A. webbiana leaf extract (400 and 600 mg/kg) showed maximum inhibition of cough frequency by 71.69% and 78.67%, respectively, when compared with the control group and was comparable in effect to codeine phosphate.
Collapse
Affiliation(s)
- S S Nayak
- Natural Science Laboratory, Department of Pharmaceutical Technology, Jadavpur University Kolkata--700 032, India
| | | | | | | | | |
Collapse
|
13
|
Abstract
The immunoassays used to measure free T4 in serum frequently underestimate free T4 concentrations. These underestimates of serum free T4 are often greater than can be attributed to sample dilution. Unrecognized T4 sequestration by assay materials could cause such underestimates, but T4 sequestration during free T4 measurements has not been well studied. To study T4 sequestration, we used simple solutions containing gravimetrically determined quantities of T4 without T4 binding proteins. T4 sequestration was calculated as the differences between the actual quantities of free T4 required to obtain a specific free T4 measurement and the quantities that would, in theory, have been required, assuming zero T4 sequestration. Sequestration occurred in every serum free T4 assay studied, was often in the nanomolar range, and varied from 26-99+% of the actual amount of free T4 required to obtain free T4 measurements. We conclude that unrecognized T4 sequestration is a major confounding variable in free T4 assay performance, and that it explains the underestimates of serum free T4 concentrations by free T4 immunoassays which cannot be explained by sample dilution.
Collapse
Affiliation(s)
- J C Nelson
- Loma Linda University School of Medicine, California 92354
| | | | | |
Collapse
|
14
|
Ramani A, Nayak SS, Gopalakrishna K, Kundaje GN. Glycemic control and its relationship to diabetic foot ulcers. INDIAN J PATHOL MICR 1991; 34:161-5. [PMID: 1818851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Glucosylhaemoglobin (HbA1) was estimated in 60 diabetic patients, 30 with foot ulceration and 30 without foot lesions. Peripheral neuropathy and vascular disease were commonly found in the ulcer' group. The mean HbA1 level in diabetics without ulcers was 9.77 +/- 2.34, while the corresponding level in diabetics with ulcers was 14.14 +/- 3.63. The difference in values is statistically highly significant (p less than 0.001) suggesting that foot ulcers are more likely to occur in poorly controlled diabetic patients.
Collapse
Affiliation(s)
- A Ramani
- Department of Medicine, Kasturba Medical College, Manipal
| | | | | | | |
Collapse
|
15
|
Nayak SS, Bhaskaranand N, Kamath KS, Baliga M, Venkatesh A, Aroor AR. Serum apolipoproteins A and B, lecithin: cholesterol acyl transferase activities and urinary cholesterol levels in nephrotic syndrome patients before and during steroid treatment. Nephron Clin Pract 1990; 54:234-9. [PMID: 2314540 DOI: 10.1159/000185861] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Serum apolipoproteins A (Apo-A) and B (Apo-B) and lecithin: cholesterol acyl transferase (LCAT) activities and 24-hour urinary cholesterol levels were estimated in 25 nephrotic children before and during steroid treatment with 4 weeks of daily prednisolone followed by another 4 weeks of alternate-day prednisolone. The patients with untreated nephrotic syndrome (NS) showed significant decrease in serum Apo-A and LCAT activities associated with significant increase in serum Apo-B and urinary cholesterol levels compared to healthy controls (n = 25). Serum Apo-A levels correlated directly and Apo-B levels inversely with the serum albumin concentrations. After a transient elevation, the serum Apo-A level returned to control range by 8 weeks of treatment accompanied by a gradual increase in serum LCAT activity and decrease in urinary cholesterol excretion. Though, the serum Apo-B level was decreased with treatment, it was still significantly high compared to the controls.
Collapse
Affiliation(s)
- S S Nayak
- Department of Clinical Biochemistry, Kasturba Medical College, Manipal, India
| | | | | | | | | | | |
Collapse
|
16
|
Nayak SS, Vasu KS, Kundaje GN, Aroor AR. HDL-cholesterol--a sensitive parameter of hepatic function in infective hepatitis. J Assoc Physicians India 1989; 37:521-3. [PMID: 2621190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
HDL-cholesterol was estimated along with other biochemical parameters of hepatic function in infective hepatitis. Infective hepatitis was characterized by significantly decreased levels of HDL-cholesterol. Follow up studies indicated a good correlation of changes in HDL-cholesterol to severity of disease in all the cases whereas standard liver function tests showed equivocal changes in some cases. HDL-cholesterol may serve as a sensitive indicator of hepatic function in infective hepatitis.
Collapse
|
17
|
Affiliation(s)
- S S Nayak
- Department of Clinical Biochemistry and Nutrition, Kasturba Medical College, Manipal, India
| | | | | | | | | |
Collapse
|
18
|
Nayak SS, Ramani A, Kamath SS, Kundaje GN, Aroor AR. Serum apoproteins A and B and the lecithin: cholesterol acyl transferase activities in liver cirrhosis and hepatic coma patients. Biochem Med Metab Biol 1988; 40:299-304. [PMID: 3233186 DOI: 10.1016/0885-4505(88)90132-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Serum apoproteins A and B and LCAT activities were estimated in 80 patients, 46 with posthepatic cirrhosis and 34 with alcoholic cirrhosis. The cirrhosis patients were also divided into compensated, decompensated, and hepatic coma subgroups. Apo-A and LCAT activities were significantly decreased in both cirrhotic groups without any significant difference between posthepatitic and alcoholic cirrhotic groups, while Apo-B was decreased in hepatic coma patients only. The decompensated cirrhosis patients showed lower Apo-A levels than the compensated cirrhosis patients and hepatic coma patients showed still lower levels compared to decompensated subgroup, while no significant decrease was observed in LCAT activities between compensated and decompensated cirrhosis patients. Apo-A level was correlated more significantly with serum albumin level than the LCAT activity. The study confirms that Apo-A level is highly related to the degree of liver injury and also suggests that this decrease may be mainly due to impaired liver synthesis and that the serum levels of Apo-A and Apo-B can be utilized in the differential diagnosis of chronic liver diseases.
Collapse
Affiliation(s)
- S S Nayak
- Department of Clinical Biochemistry and Nutrition, Kasturba Medical College, Manipal, India
| | | | | | | | | |
Collapse
|
19
|
Nayak SS, Bhaskaranand N, Baliga M, Venkatesh A, Rao PV, Aroor AR. Serum HDL-cholesterol & urinary cholesterol in nephrotic syndrome. Indian J Med Res 1988; 88:150-5. [PMID: 3198174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
20
|
Nayak SS, Kamath SS, Kundaje GN, Aroor AR. Diagnostic significance of estimation of serum apolipoprotein A along with alpha-fetoprotein in alcoholic cirrhosis and hepatocellular carcinoma patients. Clin Chim Acta 1988; 173:157-64. [PMID: 2454172 DOI: 10.1016/0009-8981(88)90253-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The serum apolipoprotein A (Apo A) and alpha-fetoprotein (AFP) were evaluated in histologically verified 30 cases of alcoholic cirrhosis and 18 cases of hepatocellular carcinoma (HCC). The latter were also divided into subgroups depending on the presence or absence of associated cirrhosis. Serum Apo A levels were found to be significantly decreased in cirrhotics (p less than 0.001) compared to controls and non-cirrhotic HCC patients. In 22 cases of alcoholic cirrhosis (AFP less than 10 ng/ml) and 12 cases of HCC (AFP greater than 600 ng/ml), the AFP levels itself were diagnostic, but in the remaining cases, AFP levels (100-600 ng/ml) were not able to differentiate between cirrhosis and malignancy. In this later group of patients with low pathological range of AFP, serum Apo A levels found to be significantly decreased in alcoholic cirrhotic patients (p less than 0.001) compared to HCC patients. Thus, estimation of Apo A levels may be helpful to interpret the AFP values at lower pathological range due to suspected liver pathology.
Collapse
Affiliation(s)
- S S Nayak
- Department of Clinical Biochemistry and Nutrition, Kasturba Medical College, Karnataka, India
| | | | | | | |
Collapse
|
21
|
Nayak SS, Pattabiraman TN. Determination of glucosylalbumin by phenol-sulphuric acid reaction in hyperglycaemia. Indian J Med Res 1982; 76:305-10. [PMID: 7174020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
22
|
Abstract
A new colorimetric method, based on the phenol sulphuric acid reaction of carbohydrates, is described for the determination of glycosylated hemoglobin. Hemolyzates were treated with 1 mol/l oxalic acid in 2 mol/l Hcl for 4 h at 100 degrees C, the protein was precipitated with trichloroacetic acid, and the free sugars and hydroxymethyl furfural in the protein free supernatant were treated with phenol and sulphuric acid to form the color. The new method is compared to the thiobarbituric acid method and the ion-exchange chromatographic method for the estimation of glycosylated hemoglobin in normals and diabetics. The increase in glycosylated hemoglobin in diabetic patients as estimated by the phenol-sulphuric acid method was more significant (P less than 0.001) than the increase observed by the thiobarbituric acid method (P less than 0.01). The correlation between the phenol-sulphuric acid method and the column method was better (r = 0.91) than the correlation between the thiobarbituric acid method and the column method (r = 0.84). No significant correlation between fasting and postprandial blood sugar level and glycosylated hemoglobin level as determined by the two colorimetric methods was observed in diabetic patients.
Collapse
|